Insiders · Profile

Pierce Christopher

EVP and Chief of Business Oper at Prelude Therapeutics. Filing since 29 Sep 2020. CIK 0001824631

Company

Date

Role

Action

Amount

Of holding

2 Sep 2021

EVP and Chief of Business Oper

Sold, plan not stated

17,000

$708.49K

81.9%

29 Apr 2021

EVP and Chief of Business Oper

Sold, plan not stated

3,295

$132.76K

46.8%

8 Apr 2021

EVP and Chief of Business Oper

Sold, plan not stated

200

$8.00K

5.1%

7 Apr 2021

EVP and Chief of Business Oper

Sold, plan not stated

828

$33.19K

18.1%

29 Sep 2020

EVP and Chief of Business Oper

Bought

3,750

$71.25K

opened

5 decisions on file.